amodiaquine hydrochloride
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
388
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
August 29, 2025
Synthesis, characterization, inhibition of β-hematin formation, lipophilicity, and antimalarial activity of metal-amodiaquine complexes.
(PubMed, J Inorg Biochem)
- "The Zn-AQ complexes were the most active in the series, comparable to AQ and more active than chloroquine diphosphate against the CQ-resistant strain PfW2. At a dose of 30 mg/kg, treatment with complex 1 increased the median survival time of the mice by 75 %. This may be due to the presence of two amodiaquine molecules in its composition."
Journal • Infectious Disease • Malaria
August 29, 2025
Epigenetically conferred ring-stage survival in Plasmodium falciparum against artemisinin treatment.
(PubMed, Nat Commun)
- "PfMYST epigenetic modulation extends to other antimalarials, including amodiaquine, pyrimethamine, chloroquine, and pyronaridine. Collectively, our findings provide important information on the epigenetic regulatory mechanism of P. falciparum RS after pulses of ART and other antimalarials."
Journal • Infectious Disease
August 28, 2025
Trajectory of Plasmodium falciparum Molecular Markers of Amodiaquine Resistance in São Tomé and Príncipe.
(PubMed, Open Forum Infect Dis)
- "Artesunate-amodiaquine has been the first-line treatment for uncomplicated malaria in São Tomé and Príncipe since 2005, following many decades of chloroquine usage. The results suggest that the introduction of artesunate-amodiaquine led to a trajectory of single nucleotide polymorphism (SNP) successive accretion in a pre-existing environment of pfcrt 76T near fixation, leading to the emergence of a dominant 86Y/Y184/1246Y haplotype. Our data support increased vigilance of artesunate-amodiaquine performance in São Tomé and Príncipe."
Biomarker • Journal • Infectious Disease • Malaria • ABCB1
August 28, 2025
In Vitro Inhibitory Effects and Molecular Mechanism of Four Theaflavins on Isozymes of CYP450 and UGTs.
(PubMed, Foods)
- "Theaflavin-3'-gallate moderately inhibited CYP1A2-catalyzed phenacetin metabolism and CYP2C8-mediated amodiaquine metabolism, with IC50 values of 8.67 μM and 10-20 μM, respectively...These findings highlight the selective inhibitory effects of theaflavins on specific hepatic enzymes, with potential implications for nutrient interactions, particularly for nutrients metabolized by CYP1A2, CYP2C8, UGT1A1, and UGT1A3. Further research is needed to explore the in vivo relevance and assess the dietary implications of theaflavin-rich black tea in nutrition and metabolism."
Journal • Preclinical • UGT1A3
August 16, 2025
Biomarkers to predict drug candidate iDILI risk
(ACS-Fall 2025)
- "We have also found that some drugs such as clozapine and amodiaquine are directly oxidized to reactive metabolites by macrophages leading to their activation. Further studies of how hepatocytes activate macrophages should lead to much better biomarkers to predict iDILI. This would have a profound effect on drug development."
Biomarker • IO biomarker • Hepatology • Infectious Disease • Inflammation • Liver Failure • CD8 • PD-1
August 18, 2025
Frequencies of molecular markers of drug resistance in the context of two different Seasonal Malaria Chemoprevention (SMC) treatment regimens in the Koulikoro health district, Mali.
(PubMed, Antimicrob Agents Chemother)
- "With growing concern about parasite resistance to sulfadoxine-pyrimethamine (SP) in West Africa, the effectiveness of dihydroartemisinin-piperaquine (DHA + PQ) was assessed as an alternative drug regimen for Seasonal Malaria Chemoprevention (SMC)...Some PfK13 non-synonymous mutations were observed in both years, including Y493H and C580R. The identification of the IRNI/IAGKAS quintuple mutant, along with emerging Pfdhps-431V and non-synonymous PfK13-Y493H variants, underscores the importance of continued surveillance of resistance markers."
Biomarker • Journal • Infectious Disease • Malaria • ABCB1
August 15, 2025
"We witnessed medicines help our children, then we became proud": experiences and acceptability of seasonal malaria chemoprevention in Aweil, South Sudan.
(PubMed, Malar J)
- "This study provides crucial insights into factors influencing acceptability of SMC in a fragile setting, which can be used to refine community engagement strategies for SMC and generate guidelines for optimizing SMC in similar challenging contexts."
Journal • Infectious Disease • Malaria
July 31, 2025
Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model.
(PubMed, Antimicrob Agents Chemother)
- "In the pharmacodynamic high parasitemia Plasmodium berghei ANKA-luciferase mouse blood-stage model, we investigated curative interaction analysis of multiple, daily dosed, short half-life, artesunate or single-dose, long half-life, pyronaridine against three single-dose, long half-life, quinolines-chloroquine, amodiaquine, and tafenoquine. Short blood half-life azithromycin, requiring multiple daily doses, was additive to artesunate or pyronaridine in fractional curative dose combination killing. Murine malaria high parasitemia drug interactions at the curative metric in vivo are a potential benchmark for human studies."
Journal • Preclinical • Infectious Disease • Malaria
July 23, 2025
Computer-aided repositioning and functional in vitro assessment of novel PAD4 inhibitors.
(PubMed, RSC Med Chem)
- "NETosis assays demonstrated that the three selected compounds altered chromatin decondensation and cellular morphology similarly to BBCla, although not uniformly across all cells. Overall, amodiaquine, folic acid, and pyroxamide were identified as PAD4 inhibitors through combined virtual and experimental approaches, supporting their potential as therapeutic candidates for PAD4-related diseases and warranting further investigation."
Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology
July 21, 2025
Rapid and cost-effective colorimetric detection of alkaloids in botanical extracts using a novel protocol with compressed tablets.
(PubMed, Sci Rep)
- "Cymbopogon Citratus (Lemon Grass), Stevia Rebaudiana (Stevia), Curcuma Longa (Turmeric), Hippophae Rhamnoides L. (Sea Buckthorn seeds), Caffeine (Panadol Extra), Mentha Piperita (Menthol) leaves were utilised as botanical samples of alkaloidal contents, while water was used as a blank, along with Amodiaquine (Basoquin) as an anti-malarial drug registered by Pfizer as a positive control for the colorimetric testing and comparison of the results. The results showed that the chemical constituents of the tablets were intact, along with the integrity of the chemical testing, respective mechanical strength, and a good shelf life of a year. The proposed water-soluble tablets for the identification of alkaloids in samples of plant sources and pharmaceutical drugs have developed considerable colorimetric detection results and displaying good mechanical strength and stable physicochemical properties which demonstrated their potential application in the field of concerned..."
HEOR • Journal • Infectious Disease
July 17, 2025
IN VITRO ASSESSMENT OF REVERSIBLE AND METABOLISM-DEPENDENT INHIBITORY EFFECTS OF PROPOXAZEPAM ON CYP2C8 ACTIVITY.
(PubMed, Exp Oncol)
- "Based on the indicators used (Ki, IC50, IC50 shift, and [I]/Ki ratios), propoxazepam is not expected to be a significant CYP2C8 inhibitor in vitro."
Journal • Preclinical • Oncology • CYP2C8
July 14, 2025
Indirect Benefits of Seasonal Malaria Chemoprevention for Non-Malarial Pediatric Infections and Routine Antibiotic Use in Real-World Programmatic Settings: A Pre-Post Study Using Positive and Negative Controls.
(PubMed, medRxiv)
- "To assess the benefits of Seasonal Malaria Chemoprevention (SMC), the monthly administration of sulfadoxine-pyrimethamine and amodiaquine during the high malaria season, beyond malaria prevention in real-world program settings. Reductions varied across SMC cycles and were most pronounced following the final round. SMC may have additional benefits beyond malaria prevention, including reductions in common pediatric infections and subsequent routine antibiotic use."
Journal • Real-world evidence • Infectious Disease • Malaria • Pediatrics • Pneumonia • Respiratory Diseases
July 02, 2025
Development of a new wealth index for South Sudan: association between household wealth and malaria prevention practices in the context of seasonal malaria chemoprevention in Northern Bahr el Ghazal, South Sudan.
(PubMed, Infect Dis Poverty)
- "The new wealth index tailored to South Sudan is a useful tool for assessing socioeconomic health determinants. While household access to SMC showed a low degree of wealth-associated disparities, reflecting the equitable coverage of the door-to-door SMC delivery model, significant inequities remain in household access to other malaria prevention practices, such as mosquito nets. These findings imply the need for strategies to enhance equity in distributing essential malaria prevention resources."
Journal • Infectious Disease • Malaria
June 16, 2025
A LC-MS/MS Assay for Quantification of Amodiaquine and Desethylamodiaquine in Dried Blood Spots on Filter Paper.
(PubMed, Int J Anal Chem)
- "Artesunate-amodiaquine (ARS-AQ) is a first-line antimalarial treatment recommended by the World Health Organization. The developed method was demonstrated to be reliable and accurate. This assay may be particularly useful in the context of resource limited settings and in pediatric field studies."
Journal • Infectious Disease • Malaria • Pediatrics
June 16, 2025
A comprehensive revision on the use of quinoline antimalarial drugs as leishmanicidal agents.
(PubMed, Front Chem)
- "and against in vivo models of eleven key antimalarials, including chloroquine, sitamaquine, amodiaquine, mefloquine, quinine, primaquine, hydroxychloroquine, tafenoquine, quinacrine and moxipraquine. Mechanistic studies and advances in clinical treatment are also discussed. This mini-review aims to show the state of the art in using antimalarial drugs to discover alternative therapies for leishmaniasis treatment."
Journal • Review • Infectious Disease
June 06, 2025
A Study on the Clinical Efficacy of Amodiaquine in the Treatment of Systemic Lupus Erythematosus
(ChiCTR)
- P=N/A | N=7 | Not yet recruiting | Sponsor: Ningbo Medical Centre Lihuili Hospital; Ningbo Medical Centre Lihuili Hospital
New trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
May 27, 2025
"I heard at home. The leader came by to inform". The role of community leaders and community distributors in promoting uptake of seasonal malaria chemoprevention in Nampula Province, Mozambique: a qualitative study.
(PubMed, BMC Public Health)
- "Involving community leaders in the mobilisation and distribution of interventions, such as SMC, helps to facilitate active participation from the community and result in greater acceptability and community uptake."
Journal • Infectious Disease • Malaria • Mood Disorders • Psychiatry
May 22, 2025
Seasonal malaria chemoprevention in northern Mozambique: a cost-effectiveness analysis.
(PubMed, Malar J)
- "In line with existing evidence from other African countries, SMC is found to be cost-effective in Mozambique. SMC is a beneficial prevention strategy to improve under-five health in the country, at a relatively low-cost."
HEOR • Journal • Infectious Disease • Malaria
May 15, 2025
ZrS2 Nanoparticles Embedded in Chitosan-Based Hydrogel for the Electrochemical Detection of Antimalarial Drug Amodiaquine in Serum Samples.
(PubMed, ACS Appl Bio Mater)
- "The repeatability and reproducibility results of the ZrS2/CS hydrogel show excellent consistent results, with relative standard deviations of 3.41 and 3.46%, respectively, further affirming the reliability of the sensor. This approach opens up future research directions for detecting various analytes in point-of-care and other biomedical devices."
Journal • Infectious Disease
May 09, 2025
Plasmodium falciparum isolates: ex vivo drug response.
(PubMed, J Antimicrob Chemother)
- "Clinical isolates from coastal Ghana remain susceptible to artemisinin derivatives in commonly used ACTs in Ghana. However, we observed lower susceptibility to the ACT partner drugs lumefantrine and amodiaquine, suggesting the emergence of drug-tolerance phenotypes. Consistent surveillance of drug phenotype-genotype is needed to support ACT efficacy in Ghana."
Journal • Preclinical • Infectious Disease • Malaria • ABCB1
May 05, 2025
A well-characterized mechanistic Model for exploring known or hypothesized T cell -mediated drug induced liver injury: current capabilities and challenges for future predictivity.
(PubMed, Expert Opin Drug Metab Toxicol)
- "To overcome deficits in quantitative data characterizing CD8+ T cell-mediated DILI, a translational strategy leveraged a well-defined mouse ovalbumin (OVA) antigen model and adapted it to represent mouse amodiaquine (AQ)-specific CD8+ T cell-mediated DILI, with further adaptations to represent human AQ-specific CD8+ T cell-mediated DILI...The DILIsym CD8+ T cell sub-model is well-positioned for systematic testing to improve our understanding of CD8+ T cell-mediated DILI. It is not yet predictive but indicates a promising direction to reduce DILI events in drug development."
Journal • Hepatology • Liver Failure • CD8
April 27, 2025
Molecular Docking, Toxicity Study and In Vitro Antimalarial Evaluation of Pyrazole Substituted 1,3,5-Triazine Derivatives.
(PubMed, Exp Parasitol)
- "The development of resistance to antimalarial drugs such as chloroquine, amodiaquine, artemisinin, and antifolates is a major health concern, prompting more research into new antimalarial therapies. Compounds 7j and 7i exhibited considerable antimalarial efficacy against chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strains of P. falciparum, with IC50 values ranging from 23.78 to 83.36 μM and 30.89 to 64.24 μM, respectively. These pyrazole-substituted 1,3,5-triazine derivatives could be utilized to find a novel class of Pf-DHFR-TS inhibitors."
Journal • Preclinical • Infectious Disease • DHFR
April 17, 2025
Design, Synthesis, and Anti-SARS-CoV-2 Activity of Amodiaquine Analogs.
(PubMed, Chem Pharm Bull (Tokyo))
- "In this study, we designed and synthesized new anti-SARS-CoV-2 drugs based on the chemical structure of amodiaquine, which is known as an antimalarial drug. Consequently, we have identified amodiaquine analogs functionalized with dialkylamino-pendant aminophenol moieties that possess a high level of anti-SARS-CoV-2 activity with a low level of toxicity."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 16, 2025
Ab-initio Molecular Dynamics and Density Functional Theory Study of Amodiaquine Analogues as Potential Inhibitors of β-haematin Crystallization.
(PubMed, Curr Med Chem)
- "The findings from this study are valuable because they can aid the design and understanding of new therapeutic molecules that could be used to treat drug-resistant malaria, a global threat of today."
Journal • Infectious Disease • Malaria
April 16, 2025
Evaluation of seasonal malaria chemoprevention implementation in the Upper East region of Northern Ghana.
(PubMed, Malar J)
- "Despite achieving an average coverage of 87% per cycle, it falls short of the national target of 90%. Notable reasons for drop-outs and non-adherence were, the caregiver being unavailable during the distribution, highlighting the need for diversified approaches in SMC campaigns to enhance coverage, and adherence, and maximize intervention benefits."
Journal • Infectious Disease • Malaria
1 to 25
Of
388
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16